Clinical Trial Update: Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 trial evaluating autologous CAR T cells in patients with advanced, platinum-resistant ovarian, fallopian tube, or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Autologous CAR T Cells

Snippet

Sponsor: Precigen, Inc | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING